Therapeutic blockade of interleukin-6 in chronic inflammatory disease

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 4, 2012, Pages 574-576

  Yamamoto, K ^a   Rose John, S ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; CHRONIC INFLAMMATION; ENTERITIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RHEUMATOID ARTHRITIS; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHRONIC DISEASE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 84863393237     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.11     Document Type: Short Survey

References (5)

1. Jones, S., Scheller, J. & Rose-John, S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 121, 3375-3383 (2011).
2. Scheller, J., Chalaris, A., Schmidt-Arras, D. & Rose-John, S. The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta 1813, 878-888 (2011).
3. Van Hauwermeiren, F., Vandenbroucke, R.E. & Libert, C. Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev. 22, 311-319 (2011).
4. Kopf, M., Bachmann, M.F. & Marsland, B.J. Averting inflammation by targeting the cytokine environment. Nat. Rev. Drug Discov. 9, 703-718 (2010).
5. Tanaka, T., Narazaki, M. & Kishimoto, T. Therapeutic targeting of the interleukin-6 receptor. Annu. Rev. Pharmacol. Toxicol. 52, 199-219 (2012).